Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT: A phase-2 trial

P Gimsing, Ø Hjertner, N Abildgaard, N F Andersen, T G Dahl, H Gregersen, T W Klausen, U-H Mellqvist, O Linder, R Lindås, N Tøffner Clausen, S Lenhoff

Research output: Contribution to journalJournal articleResearchpeer-review

10 Citations (Scopus)
Original languageEnglish
JournalBone Marrow Transplantation
Volume50
Issue number10
Pages (from-to)1306-1311
Number of pages6
ISSN0268-3369
DOIs
Publication statusPublished - 2015

Fingerprint Dive into the research topics of 'Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT: A phase-2 trial'. Together they form a unique fingerprint.

Cite this